Similar to a study that observed declines in early mortality in all MM patients including those younger than 65 years and older than 65 years [ 20 ], our findings revealed distinct characteristics in mortality but ultimately demonstrated a decreasing trend across continents.
← all excerpts
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.
1
—
—